Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 10.8
(-0.55%)
CNY 10.8
(-0.55%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -372.36 Million CNY | -53.26% |
| 2022 | -242.97 Million CNY | -13.96% |
| 2021 | -213.21 Million CNY | -37.32% |
| 2020 | -155.26 Million CNY | -863.25% |
| 2019 | 20.34 Million CNY | -86.41% |
| 2018 | 149.71 Million CNY | -50.54% |
| 2017 | 302.69 Million CNY | 2.53% |
| 2016 | 295.22 Million CNY | 24.06% |
| 2015 | 237.97 Million CNY | 16.89% |
| 2014 | 203.58 Million CNY | 63.54% |
| 2013 | 124.49 Million CNY | -35.71% |
| 2012 | 193.64 Million CNY | 61.52% |
| 2011 | 119.88 Million CNY | 87.13% |
| 2010 | 64.06 Million CNY | 64.53% |
| 2009 | 38.93 Million CNY | 123.88% |
| 2008 | 17.39 Million CNY | 325.34% |
| 2007 | 4.08 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.68 Million CNY | 60.42% |
| 2024 Q3 | -5.95 Million CNY | -252.55% |
| 2024 Q1 | -4.26 Million CNY | 97.72% |
| 2023 FY | -372.36 Million CNY | -53.26% |
| 2023 Q1 | -48.71 Million CNY | 45.09% |
| 2023 Q2 | -104.63 Million CNY | -114.77% |
| 2023 Q4 | -187.14 Million CNY | -530.09% |
| 2023 Q3 | -29.7 Million CNY | 71.61% |
| 2022 Q4 | -88.72 Million CNY | -22.96% |
| 2022 FY | -242.97 Million CNY | -13.96% |
| 2022 Q1 | -24.43 Million CNY | 71.96% |
| 2022 Q2 | -57.64 Million CNY | -135.89% |
| 2022 Q3 | -72.15 Million CNY | -25.17% |
| 2021 Q2 | -39.79 Million CNY | -100.27% |
| 2021 Q1 | -19.86 Million CNY | 73.11% |
| 2021 FY | -213.21 Million CNY | -37.32% |
| 2021 Q4 | -87.13 Million CNY | -31.21% |
| 2021 Q3 | -66.41 Million CNY | -66.9% |
| 2020 FY | -155.26 Million CNY | -863.25% |
| 2020 Q4 | -73.88 Million CNY | -219.87% |
| 2020 Q3 | -23.09 Million CNY | 31.47% |
| 2020 Q2 | -33.7 Million CNY | -37.11% |
| 2020 Q1 | -24.58 Million CNY | 21.54% |
| 2019 FY | 20.34 Million CNY | -86.41% |
| 2019 Q3 | 7.3 Million CNY | -27.64% |
| 2019 Q4 | -31.33 Million CNY | -528.69% |
| 2019 Q2 | 10.1 Million CNY | -70.52% |
| 2019 Q1 | 34.26 Million CNY | 421.84% |
| 2018 FY | 149.71 Million CNY | -50.54% |
| 2018 Q1 | 66.35 Million CNY | 48.28% |
| 2018 Q4 | 6.56 Million CNY | -76.33% |
| 2018 Q3 | 27.73 Million CNY | -43.45% |
| 2018 Q2 | 49.05 Million CNY | -26.08% |
| 2017 Q4 | 44.75 Million CNY | -53.64% |
| 2017 Q1 | 76.92 Million CNY | 26.58% |
| 2017 Q2 | 84.48 Million CNY | 9.83% |
| 2017 Q3 | 96.53 Million CNY | 14.27% |
| 2017 FY | 302.69 Million CNY | 2.53% |
| 2016 FY | 295.22 Million CNY | 24.06% |
| 2016 Q1 | 69.64 Million CNY | 109.56% |
| 2016 Q4 | 60.76 Million CNY | -34.85% |
| 2016 Q2 | 71.52 Million CNY | 2.7% |
| 2016 Q3 | 93.27 Million CNY | 30.41% |
| 2015 Q3 | 73.84 Million CNY | 9.05% |
| 2015 FY | 237.97 Million CNY | 16.89% |
| 2015 Q4 | 33.23 Million CNY | -54.99% |
| 2015 Q2 | 67.71 Million CNY | 7.17% |
| 2015 Q1 | 63.18 Million CNY | 5.2% |
| 2014 Q4 | 60.06 Million CNY | -18.29% |
| 2014 FY | 203.58 Million CNY | 63.54% |
| 2014 Q1 | 42.2 Million CNY | 1492.28% |
| 2014 Q2 | 27.81 Million CNY | -34.1% |
| 2014 Q3 | 73.5 Million CNY | 164.27% |
| 2013 Q3 | 14.9 Million CNY | -72.57% |
| 2013 Q4 | -3.03 Million CNY | -120.34% |
| 2013 FY | 124.49 Million CNY | -35.71% |
| 2013 Q1 | 58.28 Million CNY | 23.3% |
| 2013 Q2 | 54.32 Million CNY | -6.79% |
| 2012 Q1 | 42.1 Million CNY | -18.86% |
| 2012 Q4 | 47.27 Million CNY | 15.76% |
| 2012 Q2 | 63.43 Million CNY | 50.67% |
| 2012 Q3 | 40.83 Million CNY | -35.62% |
| 2012 FY | 193.64 Million CNY | 61.52% |
| 2011 Q1 | 13.9 Million CNY | -32.87% |
| 2011 FY | 119.88 Million CNY | 87.13% |
| 2011 Q3 | 29.56 Million CNY | 20.54% |
| 2011 Q4 | 51.88 Million CNY | 75.5% |
| 2011 Q2 | 24.52 Million CNY | 76.34% |
| 2010 Q2 | 14.79 Million CNY | 0.31% |
| 2010 FY | 64.06 Million CNY | 64.53% |
| 2010 Q3 | 13.33 Million CNY | -9.9% |
| 2010 Q1 | 14.75 Million CNY | 0.0% |
| 2010 Q4 | 20.71 Million CNY | 55.41% |
| 2009 FY | 38.93 Million CNY | 123.88% |
| 2008 FY | 17.39 Million CNY | 325.34% |
| 2007 FY | 4.08 Million CNY | 0.0% |